Table 1 Laboratory assays responsive to NOACs [25, 28, 29]
From: Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
| Â | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | Issues related to testing |
|---|---|---|---|---|---|
PT | Insensitive at therapeutic concentrations | Normal PT can exclude significant drug levels | Insensitive | Poor sensitivity | Highly variable based on reagent; cannot be standardized across laboratories |
aPTT | Normal aPTT can exclude anticoagulation | Insensitive | Insensitive | Dose-dependent prolongation | Highly variable based on reagent; cannot be standardized across laboratories Clinical relevance of recovery unknown |
TT | Highly sensitive, must be diluted Normal values can exclude anticoagulation | Insensitive | Insensitive | Insensitive | Preferred assay for dabigatran; reagent-dependent |
Anti-FXa | Insensitive | Sensitive when calibrated; normal FXa can exclude anticoagulation | Sensitive when calibrated; normal FXa can exclude anticoagulation | Sensitive when calibrated; normal FXa can exclude anticoagulation | Variable range, interlaboratory variability, not widely available. Preferred assay for rivaroxaban, apixaban, and edoxaban |